Demystifying NPM1 in AML: What It Means and Why It Matters
Join us for the next session in our AML genetics series as we explore the NPM1 mutation—one of the most common genetic changes found in acute myeloid leukemia (AML). Dr. Shai Shimony, a physician in Medical Oncology at Dana-Farber Cancer Institute, will walk us through what NPM1 is, how it impacts diagnosis and treatment decisions, and why it’s important in understanding your specific type of AML. Whether you’re newly diagnosed or looking to understand your AML journey better, this session will help you feel more informed and confident when speaking with your care team.
Mary introduces the agenda for the event and featured speaker Shai Shimony MD, MPH
Dr. Shimony talks about NPM1 in AML
Type your questions in the chat and we will answer them!
Mary Arnett
Mary joined HealthTree in 2022 as a part of HealthTree's team to help expand into all blood cancers. She now works as HealthTree's Volunteer & Community Outreach Manager, helping to engage and involve community members in HealthTree's mission. When she isn't working, she loves being the fun aunt to her 13 nieces and nephews, attending concerts, experimenting with new recipes in the kitchen, and traveling to explore new cities.
Shai Shimony MD, MPH
Dr. Shai Shimony is a leukemia specialist with advanced training from Dana-Farber Cancer Institute and a Master’s in Clinical Effectiveness from Harvard. His clinical and research focus centers around improving care and outcomes for patients with acute leukemias, especially AML, ALL, and rare subtypes like BPDCN.